Skip to main content
OpenTrials
Completed

NCT Number: NCT04413916

MiRNA in Kidney Transplantation: Association With Kidney Graft Function and Disease Process

MicroRNAs (miRNAs) belong to a class of small non-coding RNAs that modulate physiological and pathological processes by post-transcriptional regulation of gene expression mainly via translational inhibition of target messenger RNAs. Recently, many miRNAs were found to be involved in pathological processes that occur following kidney transplantation, like allograft rejection, de novo disease or disease recurrence after kidney transplantation. As most of the miRNAs involved in kidney diseases are extracted by urine, the diagnostic accuracy of such molecules as biomarkers is questionable.

The aim of this study is to analyze expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) and evaluate whether their regulation is associated with kidney graft function and disease processes after kidney transplantation (KTx).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Kidney Transplant Failure and Rejection Behavior Rejection, Psychology Social Behavior

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Medical Centre Ljubljana

Ljubljana, 1000, Slovenia

About this study

MicroRNAs (miRNA) are short, endogenous non-coding RNAs involved in the modulation of gene expression mainly by inhibition of messenger RNAs translation. Recent studies have indicated association of miRNAs with pathological processes following kidney transplantation.

The aim of the study is to determine whether selected miRNAs are related to specific disease process or only reflect kidney graft function.

The study enrolled 100 Caucasian KTRs, who presented with stable renal function (as indicated by stable serum creatinine (Cr) for 3 months and whose kidney graft function was thereafter estimated with various methods, including: cystatin C concentration, three different CKD EPI equations and measured with chromium-51 ethylenediamine tetraacetic acid clearance.

Expression of 6 selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, and miR-223) was determined by qPCR using miRNA-103a, miR-191, and miR-423 as reference genes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • time of kidney transplantation at least 2 years before the study entry,
  • stable function of the transplanted kidney during the previous 3 months (changes in s-creatinine ≤ 20%).

Exclusion criteria

  • age less than 18 years,
  • symptomatic heart failure,
  • malignancy,
  • pregnancy or lactation,
  • acute conditions and diseases that can affect the GFR,
  • newly-introduced drugs that may affect the function of the graft,
  • treatment with trimethoprim-sulfamethoxazole or cimetidine,
  • the presence of a pacemaker or any other electronic device in the body.

Treatment and study plan

miRNA expression

Diagnostic Test

Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.

Primary outcomes

  1. Association of miRNA and kidney graft function

    Time frame: sample collection within one month of enrollement

    correlation of selected miRNAs expression with parameters of kidney graft function

Secondary outcomes

  1. Association of miRNAs expression and kidney graft rejection or disease recurrence

    Time frame: 2 years

    Correlation of selected miRNAs expression and kidney graft rejection or disease recurrence

Sponsors and collaborators

Lead sponsor

University Medical Centre Ljubljana

Other

Registry information

Official study title

ASSOCIATION OF miRNA WITH ALLOGRAFT FUNCTION AND EXPRESSION PROFILES PREDICTIVE OF DISEASES OCCURING AFTER KIDNEY TRANSPLANTATION

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Jun 4, 2020
Registry last updated
Jun 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.